Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
OncoTrack - Methods for systematic next generation oncology biomarker development (ONCOTRACK)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Innovative Medicines Initiative
Action type: Collaborative project
Partnership: IMI (Art-185)
Countries involved: Germany,Germany,Sweden,United Kingdom,France,France,Austria,Germany,Sweden,Germany,Belgium,Germany,Switzerland,Spain
Call:  (IMI-JU-02-2009, 2009)
Start date: 2011-01-01
End date: 2016-12-31
Duration (months): 72.0
Total project cost (EUR): 31080319.0
EU funding (EUR): 16757282.0
Participants: 22
Project status: CLOSED

We propose here an exhaustive analysis of the genome, exome, methylome and transcriptome of primary tumours and metastases from patients with colon carcinoma, based on a combination of deep sequencing and chip based techniques. Dependent on their availability, we shall also perform analyses of tumor stem cells, circulating tumor cells, free tumor DNA in serum and xenografts derived from the same patients. This will be complemented by the development and application of highly sensitive techniques to identify individual mutations, transcripts and proteins/protein complexes both in-situ in pathology slides as well as in patients’ blood or serum. The integration of these results will allow us to address the heterogeneity of the tumor samples, to deduce the genome/epigenome/transcriptome of the different cell types making up or originating from the tumor (e.g. circulating tumor cells, tumour stem cells or xenografts), to establish models able to predict suitable candidates for further biomarker development, and also to predict the effects and side effects of drugs in the treatment of genetically defined groups of patients. Available biomarkers, as well as biomarkers predicted from the work within the project will be validated in patient derived xenograft models and stem cell cultures, and ultimately transferred into a point of care (POC) diagnostic format. In parallel we will explore the use of the global genome and methylome information, e.g. derived from the analysis of free tumor DNA in the serum of the patient, as the ‘ultimate’ biomarker, to model the biology of the tumor (possibly even before any tumor has been localised), and as an independent route to predict clinically relevant parameters. Though sequencing/methylation analysis of the genome of the tumor through free DNA is currently still too costly for use as a routine diagnostic, this is likely to change over the period covered by the grant, due to the extremely rapid progress in the development of large scale sequencing techniques.

Keywords: oncology,analysis,biomarker,cancer,gene,tumor,methods,sequencing techniques
Model-based preclinical development of anti-tuberculosis drug combinations (PREDICT-TB)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Innovative Medicines Initiative
Action type: Collaborative project
Partnership: IMI (Art-185)
Countries involved: Spain,United Kingdom,Germany,Netherlands,France,United Kingdom,Switzerland,United Kingdom,Netherlands,Sweden,France,Belgium,United Kingdom
Call:  (IMI-JU-03-2010, 2010)
Start date: 2012-05-01
End date: 2017-10-31
Duration (months): 66.0
Total project cost (EUR): 28553086.0
EU funding (EUR): 14778855.0
Participants: 20
Project status: CLOSED

Drug development in TB requires new integrated methods to transition the novel combination regimens needed to shorten first-line therapy and combat multi-drug resistance. Although new agents are emerging, the path to registration of such regimens remains uncertain while capacity for pivotal trials is limited. Selection and optimization of drug combinations for development depends on preclinical systems which do not capture in vivo pharmacodynamics of heterogeneous states of M.tuberculosis.These systems are diverse and their predictive power for clinical trial outcomes is uncertain, escalating risks during development. To overcome these bottlenecks, PreDiCT-TB will take a comprehensive model based approach, synthesizing and integrating preclinical and clinical information. We will harness innovative technologies to develop an integrated set of predictive pre-clinical tools to facilitate selection of the best drug combinations and dosages for entry into optimized clinical studies. We will develop diverse existing and innovative experimental models of pharmacodynamics from extracellular MTB organisms, through to acute and chronic animal models in different species. We will enhance these systems using innovative single cell and functional imaging, novel mycobacteriological approaches and identification of biomarkers of lethality and sterilization. We will represent these critical data using multi-scale mathematical approaches incorporating PK-PD and disease models, supported by a translational data integration platform.The aim is an optimized decision pathway for combination regimens to progress to innovative early clinical trials. We will develop this modelling framework using a training set of reference compounds and subsequently update it with emerging data from new compounds. We believe that this comprehensive approach is the only way to overcome existing gaps in translation and create an effective and rapid drug development strategy for European researchers.

Keywords: tuberculosis,pkpd modelling,in vitro systems,animal models,clinical trials,translational medicine
Oral biopharmaceutics tools (ORBITO)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Innovative Medicines Initiative
Action type: Collaborative project
Partnership: IMI (Art-185)
Countries involved: Sweden,Sweden,United Kingdom,Germany,Greece,Netherlands,Germany,Germany,United Kingdom,Denmark,Belgium,Germany,Germany,Germany,Belgium,United States,Switzerland,Finland,France,United Kingdom
Call:  (IMI-JU-04-2011, 2011)
Start date: 2012-10-01
End date: 2018-09-30
Duration (months): 72.0
Total project cost (EUR): 25274674.0
EU funding (EUR): 8975392.0
Participants: 27
Project status: CLOSED

The OrBiTo project will deliver novel methods and a framework for rational application of predictive biopharmaceutics tools for oral drug delivery. This will be achieved through novel propsective studies to define new methodlogies which will be validated using historical datasets from EFPIA partners. A combination of high quality in vitro or in silico characterizations of API and formulations will be integrated into physiologically based in silico models capturing the full complexity of oral drug absorption. This approach will drive model based pharmaceutical product development in accordance with visions of Quality by Design. Benefits include an accelerated formulation development process, particularly for challenging projects e.g. for low solubility molecules or modified-release formulations as well as allowing optimization of clinical product performance for patient benefit. In addition, it will significantly reduce the need for future animal experiments in this area and reduce the need for human bioequivalence studies for bridging between formulations within clinical programmes. The consortium is composed of world-leading scientists in a unique multidisciplinary collaboration where competences from nine academic partners, one regulatory agency, one non-profit research organisation and three SMEs are brought together with the twelve EFPIA partners giving an unparalleled opportunity to deliver transformational change in European industrial product development.

Keywords: biopharmaceutics,oral absorption,predictive tools
Lithography Enhancement towards Nano Scale (LENS)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Electronic Numerical Integrator and Computer
Action type: Collaborative project
Partnership: ENIAC (Art-185)
Countries involved: Italy,Netherlands,France,France,Belgium,Spain,Spain
Call:  (JU-ENIAC-2008-1, 2008)
Start date: 2009-01-01
End date: 2011-12-01
Duration (months): 35.0
Total project cost (EUR): 30562238.0
EU funding (EUR): 5103951.0
Participants: 12
Project status: CLOSED

Water immersion lithography has been widely accepted as patterning technology for the 45nm technology node, but solutions for the patterning of 32nm and 22nm technology nodes are not clear yet. EUV lithography is not yet available for industrial use, in spite of the impressive progresses registered till now, while multiple beam e beam lithography is still in development. Double patterning seems to be the only viable option to support the development of future process generations in a cost effective way and within the time limits defined by ITRS roadmap. Its main advantage consists in enabling the definition of structures beyond resolution capability of existing lithographic tools, without drastic changes in manufacturing infrastructures or huge investments. Two alternative approaches are possible, both based on existing immersion scanners: Double exposure, which implies two subsequent exposure steps, and the use of different combinations of hard masks or innovative resist materials and development process; Pitch doubling based on a single lithography exposure followed by the formation of spacers, by material deposition and etch-back, also in combination with CMP. Both approaches are being actively investigated, but they are still far from maturity. Among the problems to be solved there is the control of mask to mask alignment, for double exposure, and the control of the thickness of deposited layers, of defects and of profiles, for pitch doubling. Common concerns are cost, size control and the partitioning of the design. The pitch doubling approach is the more advanced, specially for memories, while double exposure could have a broader application, but will require improvement to equipment. The consortium includes all required competences to develop all elements of the supply chain required to bring double patterning to industrial maturity, in order to support 32nm and 22nm node mass production.

Keywords: lithography,metrology,design,opc,ret
Millimeter-wave and Radio-frequency integration in Nanoelectronics for Modern Wireless 5 A Communications (MIRANDELA)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Electronic Numerical Integrator and Computer
Action type: Collaborative project
Partnership: ENIAC (Art-185)
Countries involved: France,Italy,Greece,France,Belgium,Spain,Italy,France,Austria,Finland,Norway,Netherlands,Greece,Switzerland,France,France,United Kingdom
Call:  (ENIAC-2009-1, 2009)
Start date: 2010-05-01
End date: 2013-04-01
Duration (months): 35.0
Total project cost (EUR): 49178780.0
EU funding (EUR): 8212855.0
Participants: 26
Project status: CLOSED

The ENIAC JU project MIRANDELA is building a complete digital, mixed-signal, analogue, radio frequency (RF) and millimetre-wave (MMW) platform for the design and production of chips for future wireless communications to address the challenge of transferring anything, from/to anybody, anywhere, at any time and through any path. Components in core CMOS technology and other processes will be characterised, optimised and modelled in the RF and MMW range as well as for analogue operation targeting very low power design of RF blocks and functions. Solutions will be developed to cut costs and time to market.
Cypriot Researchers Contribute to our Quality of Life (5CYRQOL)

Framework: FP7 — People
Programme: Marie-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: European Researchers' Night
Action type: Coordination and support actions
Countries involved: Cyprus
Call:  (FP7-PEOPLE-2007-5-1-1-NIGHT, 2007)
Start date: 2007-05-01
End date: 2007-10-31
Duration (months): 6.0
Total project cost (EUR): 84024.0
EU funding (EUR): 70000.0
Participants: 7
Project status: CLOSED

The proposal submitted intends to bring closer together the research community and the general public in Cyprus during the organisation of an informal, though highly important event, on the 28th September 2007. The proposed activities will aim at (a) Bringing together the research community of Cyprus with the wider public (b) Showing to the visitors how research improves our quality of life (c) Increasing awareness about the importance of European research (d) Increasing the interest of younger generation in research activities. Activities will be addressed to the large public, whichever their gender, age, social status or level of scientific training and will be based on the active involvement of researchers. The major central event for the Researchers' Night 2007 will be taking place in Nicosia at the Olympic House and Park of the Cyprus Olympic Committee. During the event the following activities will be organised: (a) Exhibition divided into 5 thematic areas, named as the "Five Circles of Quality of Life", inspired by the venue. The 5 thematic areas are Health, Environment, Social Sciences and Humanities, Horizontal Applications of Technology and Sports Sciences (b) Award Ceremony for Cypriot research / enterprise participating in important EU-funded research project (c) Award Ceremony for the winners of the Research Promotion Foundation's competition for schoolchildren and undergraduate students (d) Award Ceremony for the drawing competition "Let's Draw a Researcher" (e) Music concert with the participation of various bands (f) Knowledge-based games. Various other activities are also foreseen across Cyprus, including tours of research facilities by school children. Promotion will be a major part of the project and will be achieved with the collaboration of the local media.

Keywords: researcher night,promoting research,raising awareness
GENETIC AND GENOMIC STUDY OF CELL COMPETITION IN DROSOPHILA (SUPERCOMPETITORS)

Framework: FP7 — Ideas
Programme: European Research Council
Theme: European research council
Destination: Starting grants
Action type: Support for frontier research (ERC)
Panel: Molecular and Structural Biology and Biochemistry
Countries involved: Switzerland,Spain
Call:  (ERC-2007-StG, 2007)
Start date: 2008-09-01
End date: 2013-08-31
Duration (months): 60.0
Total project cost (EUR): 970100.0
EU funding (EUR): 970100.0
Participants: 2
Project status: CLOSED

During initial stages a cell accumulating tumor-promoting mutations is usually surrounded by normal cells. Current cancer models do not incorporate this transition from a single cell to a field of cells, although it is probably critical, since the behavior of an individual tumor cell within the cell community has to be dictated by the hard-wired genetic program that controls its aberrant cell biology and modulated by the plastic interactions with neighboring normal cells. Study of model organisms, such as yeast, C. elegans, or Drosophila, has historically pioneered crucial contributions to processes with important implications in neoplasia. Recent work in Drosophila has proposed a role for cell-competition and super-competition in early stages of cancer formation. Cell competition is a type of cell-cell interaction in which more competitive cells replace less competitive cells (Morata and Ripoll, 1975; Moreno et al. 2002). During the last year, my laboratory has performed the first microarrays to find genes involved in cell competition, as well as developed an in vitro system for cell competition. The genes identified in the microarrays are not downstream dMyc but are rather induced at the boundaries where cell competition takes place and seem to be upstream apoptosis induction. The new genes will be studied in vivo in Drosophila and in vitro with RNAi. We will also perform other microarray settings to subdivide the genes in different categories. Thanks to the complete genome sequences of both Drosophila and humans, those genes could be used to find human homologues that could serve as novel markers and targets for the detection and/or treatment of cancer at earlier stages. The possible use of cell competition as a tool for cell replacement will also be pursued. We expect to patent at least two or three of the novel uncharacterized genes with human homologs.

Keywords: cell competition,supercompetitors,cancer,drosophila
Quantifying Energy Circulation in Space Plasma (QUESPACE)

Framework: FP7 — Ideas
Programme: European Research Council
Theme: European research council
Destination: Starting grants
Action type: Support for frontier research (ERC)
Panel: Systems and communication engineering
Countries involved: Finland
Call:  (ERC-2007-StG, 2007)
Start date: 2008-09-01
End date: 2013-08-31
Duration (months): 60.0
Total project cost (EUR): 699985.0
EU funding (EUR): 699985.0
Participants: 1
Project status: CLOSED

The project aims to quantify energy circulation in space plasmas. Scientifically, energy transfer is a fundamental plasma physical problem having many applications in a variety of plasma environments ranging from coronal heating on the Sun to electric heating in the ionosphere. Technologically, understanding the plasma and energy transport properties is a step toward predictions of the space environment needed for spacecraft design and operations. The space physics community lacks an accurate and self-consistent numerical model capable of describing the global plasma system in particular in the inner magnetosphere, where major magnetic storms can cause serious damage to space-borne technology. The project has two goals: 1. Novel integration of observations from ESA’s four-spacecraft Cluster mission with simulation results to gain quantitative understanding of global energy transport properties in the near-Earth space; 2. Development of a new self-consistent global plasma simulation that describes multi-component and multi-temperature plasmas to resolve non-MHD processes that currently cannot be self-consistently described by the existing global plasma simulations. The new simulation methods are now feasible due to the increased computational capabilities. Our existing simulation environment and unique analysis methods have brought exciting new results on magnetospheric energy circulation. Seven years after launch, the Cluster database is now large enough to quantitatively assess these effects. The proposing team has a long record in observational research of global energetics and a world-leading role in developing global magnetospheric computer simulations.

Keywords: space physics magnetosphere ionosphere solar wind numerical modelling computational physics plasma space weather
European Researchers' Night in Turkey - 2 (EUREN-TR-2)

Framework: FP7 — People
Programme: Marie-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: European Researchers' Night
Action type: Coordination and support actions
Countries involved: Türkiye
Call:  (FP7-PEOPLE-2007-5-1-1-NIGHT, 2007)
Start date: 2007-06-01
End date: 2007-11-30
Duration (months): 6.0
Total project cost (EUR): 85000.0
EU funding (EUR): 76500.0
Participants: 2
Project status: CLOSED

The overall objective of the proposal is to organize the European Researchers’ Night 2007 in Turkey, building on our wide experience with the “first and only” event in Turkey last year, in order to provide the general public and in particular, young people with the opportunity to meet researchers within the context of festive and “out-of-the-ordinary” activities. The ultimate aim is to enhance public recognition of researchers and their role in society as well as to encourage more young people to embark on careers in science and consequently to increase Europe’s (and Turkey’s) attractiveness as a place of work for researchers, while providing a wider public awareness about the EU support to science & research. The project objective will be achieved by activities designed to attract and entertain the participants of different age groups and backgrounds and to deliver them the main message that “researchers are normal people. The strategic objectives of EUREN-TR-2 are: 1.to organize the European Researchers’ Night 2007 in Turkey and thus to become “a traditional Fall randez-vous” with researchers, 2.to address a large public with particular attention to young people (12+), 3.to enhance public recognition and respect of researchers and their roles in society, through extensive media coverage, 4.to create an awareness for the resources EC devotes to R&D and the improvement of working conditions for researchers, 5.to encourage the young people to embark on scientific careers 6.to emphasize the importance of science for further development of technology and industry. The project will promote the activity and increase awareness of general objectives prior to the event, organize festive and “out-of-the-ordinary” activities during the event and monitor and disseminate the results during and after the event.

Keywords: science and society,researchers,career in science,public perception of science and researchers
THE SYNTHESIS OF DIAZOBENZOFLUORENE ANTITUMOR ANTIBIOTICS: LOMAIVITICINS A, B AND KINAMYCIN C (LOMAIVITICINS)

Framework: FP7 — People
Programme: Marie-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: International Re-integration Grants
Action type: Support for training and career development of researchers (Marie Curie)
Countries involved: Greece
Call:  (FP7-PEOPLE-2007-4-3-IRG, 2007)
Start date: 2008-09-01
End date: 2012-08-31
Duration (months): 48.0
Total project cost (EUR): 100000.0
EU funding (EUR): 100000.0
Participants: 1
Project status: CLOSED

The proposed research describes a strategy for the convergent synthesis of diazobenzofluorene containing antitumor antibiotics Lomaiviticins A and B as well as the structurally related Kinamycin C. They are potent DNA cleaving agents and exhibit remarkable activity against a broad spectrum of cancer cell lines. These structurally novel antitumor antibiotics have a unique cytotoxicity profile, compared to other known DNA-damaging anticancer drugs such as adriamycin and mitomycin C, which may suggest a different mechanism of interaction with DNA. However, the currently limited availability of these compounds isolated by fermentation and the present lack of any methodology to generate synthetic analogs could hamper further research in the analysis of these highly potent DNA-cleaving agents. Access to these natural products as well as their analogs by means of chemical synthesis, would enable the scientific community to elucidate their mode of action and the origin of their cytotoxicity. Thus, in the absence of an alternative state of the art and given the potential of these molecules to become therapeutic cancer agents, the main objectives of the proposed project are: a) the development of a synthetic methodology for the convergent synthesis of lomaiviticins and their analogs, b) extension of this methodology towards the synthesis of the structurally related antitumor antibiotic kinamycin C, and c) the design and synthesis of structurally diverse diazobenzo[a]fluorene analogs aiming to identify new cytotoxic agents and some of the structural features required for their biological activity.

Keywords: organic chemistry,pharmaceutical chemistry,combinatorial chemistry,oncology